Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
37actual
Sites
27
Countries
Australia, Canada, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-13 | actual | When the study began enrolling |
| Primary completion | 2026-01-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-22 | actual | The whole study's end, after follow-up |
| First posted | 2023-04-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Intervention
- Drug: AMG 305
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants who Experience Dose Limiting Toxicities (DLTs)
measured Day 1 to Day 28
Percentage of Participants who Experience Treatment-Emergent Adverse Events (TEAEs)
measured Up to a maximum of 2 years
Percentage of Participants who Experience Treatment-Related Adverse Events
measured Up to a maximum of 2 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed